Kodiak Sciences Inc. (NASDAQ:KOD) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Kodiak Sciences Inc. (NASDAQ:KOD) have earned a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have issued a buy recommendation on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $42.1429.

KOD has been the topic of several analyst reports. Chardan Capital upgraded Kodiak Sciences from a “neutral” rating to a “buy” rating and raised their target price for the company from $14.00 to $61.00 in a report on Monday, May 11th. Wall Street Zen upgraded Kodiak Sciences from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. HC Wainwright reaffirmed a “buy” rating and issued a $58.00 price objective (up from $38.00) on shares of Kodiak Sciences in a research report on Friday, March 27th. Finally, UBS Group lifted their price objective on shares of Kodiak Sciences from $50.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, March 27th.

Institutional Investors Weigh In On Kodiak Sciences

Large investors have recently added to or reduced their stakes in the company. Westfuller Advisors LLC purchased a new stake in Kodiak Sciences during the 1st quarter worth $26,000. V Square Quantitative Management LLC purchased a new position in Kodiak Sciences in the 1st quarter valued at about $26,000. EverSource Wealth Advisors LLC boosted its position in Kodiak Sciences by 1,221.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock valued at $28,000 after buying an additional 916 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Kodiak Sciences during the fourth quarter valued at about $29,000. Finally, Headlands Technologies LLC grew its stake in shares of Kodiak Sciences by 256.4% during the second quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock valued at $30,000 after acquiring an additional 5,815 shares in the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

Kodiak Sciences Trading Down 1.4%

Shares of Kodiak Sciences stock opened at $40.08 on Friday. The company has a fifty day moving average price of $36.91 and a 200 day moving average price of $32.36. Kodiak Sciences has a twelve month low of $4.22 and a twelve month high of $47.84. The stock has a market cap of $2.51 billion, a price-to-earnings ratio of -9.61 and a beta of 2.19.

Kodiak Sciences (NASDAQ:KOD) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.93) by ($0.01). Analysts forecast that Kodiak Sciences will post -3.89 earnings per share for the current year.

About Kodiak Sciences

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.